{
  "cg:id": "Ex012",
  "cg:type": "Example",
  "dataId": {
    "cg:id": "CritAssess286",
    "cg:type": "CriterionAssessment",
    "explanation": "The RASopathy group considers MEK and ERK activation assays as well validated.",
    "criterion": {
      "cg:id": "PS3",
      "cg:type": "Criterion",
      "description": "Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product",
      "shortDescription": "Well-established functional studies showing damaging effect",
      "defaultStrength": "CG-evidence-strength:ps",
      "targetInterpretation": "LN:LA6668-3"
    },
    "variant": {
      "cg:id": "CanAll020",
      "cg:type": "CanonicalAllele",
      "preferredCtxAllele": "CtxAll023",
      "identifier": "http://reg.genome.network/allele/CA220161"
    },
    "condition": [
      {
        "cg:id": "-"
      }
    ],
    "outcome": "CG-criterion-outcome:met",
    "hasSupportingEvidence": [
      {
        "cg:id": "EvLn017",
        "cg:type": "EvidenceLine",
        "supportingData": [
          {
            "cg:id": "Func026",
            "cg:type": "FunctionalData",
            "result": "abnormal/deceased MEK activtation.",
            "dataType": "CG-func-data-type:activation",
            "contextualAllele": {
              "cg:id": "CtxAll024",
              "cg:type": "ContextualAllele",
              "relatedCanonicalAllele": {
                "cg:id": "CanAll021",
                "cg:type": "CanonicalAllele",
                "preferredCtxAllele": "CtxAll024",
                "identifier": "http://reg.genome.network/allele/CA093846"
              },
              "alleleName": "NP_004324.2:p.Gly596Val"
            },
            "gene": {
              "cg:id": "G014",
              "cg:type": "Gene",
              "symbol": "MEK"
            }
          }
        ]
      },
      {
        "cg:id": "EvLn018",
        "cg:type": "EvidenceLine",
        "supportingData": [
          {
            "cg:id": "Func027",
            "cg:type": "FunctionalData",
            "result": "abnormal/deceased ERK activtation.",
            "dataType": "CG-func-data-type:activation",
            "contextualAllele": {
              "cg:id": "CtxAll024",
              "cg:type": "ContextualAllele",
              "relatedCanonicalAllele": {
                "cg:id": "CanAll021",
                "cg:type": "CanonicalAllele",
                "preferredCtxAllele": "CtxAll024",
                "identifier": "http://reg.genome.network/allele/CA093846"
              },
              "alleleName": "NP_004324.2:p.Gly596Val"
            },
            "gene": {
              "cg:id": "G015",
              "cg:type": "Gene",
              "symbol": "ERK"
            }
          }
        ]
      }
    ],
    "contribution": [
      {
        "cg:id": "Contrib410",
        "cg:type": "Contribution",
        "agent": "Harry Stevenson",
        "onDate": {
          "cg:id": "2016-06-04T07:12:00+00:00"
        },
        "role": "CG-contributory-role:assessor"
      },
      {
        "cg:id": "Contrib411",
        "cg:type": "Contribution",
        "agent": "Noonan/Rasopathy WG (ClinGen)",
        "onDate": {
          "cg:id": "2016-06-04T07:12:00+00:00"
        },
        "role": "CG-contributory-role:assessor"
      }
    ]
  },
  "index": 3,
  "author": "Steven Harrison",
  "description": "Assessed variant: NM_004333.4(BRAF):c.1787G>T (p.Gly596Val)  \nThe RASopathy group decided for BRAF both MEK activation and ERK activation assays (in which the variant results in abnormal pattern of pERK/ERK or pMEK/MEK) is a validated assay.\nPMID:16439621 shows that Gly596Val results in abnormal/decreased MEK and ERK activiation so PS3 is applicable for this variant "
}
